Pharma Deals Review, Vol 2004, No 43 (2004)

Font Size:  Small  Medium  Large

Roche Reinvigorates Anti-Infective Franchise with Sankyo’s Antibiotic

Business Review Editor

Abstract


F. Hoffmann-La Roche acquired the exclusive rights to develop and commercialize Sankyo’s novel parenteral carbapenum antibiotic, CS-023 in US and Europe. CS-023 is indicated for the treatment of severe infections in intensive care units.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.